RET and non-small cell lung carcinoma: 39 advanced NSCLC patients (34 LAC, 5 LSCC, stages III–IV) had 78.21% overall concordance between tumor tissue and cfDNA (96); point mutations, indels, and gene rearrangements (EML4-ALK, KIF5B-RET) were considered.